Annovis Discloses Only ~$2.8M Cash at Sept 30 — Days After NYSE Listing Deficiency Notice
ANVS is trading near its 52-week low of $0.93 (5.3% below the low).
Summary
Annovis preliminarily reported about $2.8 million of cash as of September 30, 2026, filed the same day stockholders approved doubling authorized shares to 140 million. With a fresh NYSE listing deficiency notice outstanding, the company has minimal runway and a newly enlarged share authorization to raise capital against.
Key Events · Earnings and Guidance · ANVS
-
Preliminary Q3 Cash of ~$2.8M
Annovis estimates cash and cash equivalents of approximately $2.8 million as of September 30, 2026 — preliminary, unaudited and not reviewed by its auditors.
-
Runway Looks Very Thin
The $2.8 million balance compares with $18.7 million in cash reported at the Q2 2026 update on August 14, 2026, implying roughly $15.9 million consumed in the quarter (18.7 - 2.8 = 15.9).
-
NYSE Listing Deficiency Outstanding
The October 29, 2026 NYSE notice that Annovis fails Section 802.01B remains unresolved; the enlarged authorization does not by itself cure the market-cap shortfall.
-
140M Authorized Shares Cleared Same Day
Stockholders approved doubling authorized common stock from 70 million to 140 million, with the charter amendment filed in Delaware on November 4, 2026; no shares have been issued under it.
Analysis · ANVS · Life Sciences
Annovis ended the third quarter with roughly $2.8 million in cash, a preliminary figure disclosed the same day shareholders approved doubling authorized shares to 140 million. That combination is the story: the company has very little runway left, has just cleared the way to issue more stock, and is already on notice from the NYSE that its market cap has fallen below the continued-listing standard. The cash number is unaudited and subject to change, but at this level the next equity raise is a question of when, not if — and it will come at a share price near the 52-week low.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $0.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.93 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.